Genmab Reports Phase 2 ORRs of 75% and 67% in mCRC
Genmab reported updated results for petosemtamab plus FOLFOX/FOLFIRI, with ORRs of 75% in first-line and 67% in second-line patients. ORR was 81% in first-line left-sided tumors; the data support ongoing global Phase 3 trials.
Genmab reported updated Phase 2 data for petosemtamab + FOLFOX/FOLFIRI in mCRC: ORR 75% in 1L and 67% in 2L, with 81% in 1L left—sided tumors. Most prior unconfirmed responses were confirmed; data support ongoing global Phase 3 trials.Material DetailsContext by AI AnalystThis is mid-stage efficacy…